e Eggerthella lenta is an emerging pathogen that has been underrecognized due to historical difficulties with phenotypic identification. Until now, its pathogenicity, antimicrobial susceptibility profile, and optimal treatment have been poorly characterized. In this article, we report the largest cohort of patients with E. lenta bacteremia to date and describe in detail their clinical features, microbiologic characteristics, treatment, and outcomes. We identified 33 patients; the median age was 68 years, and there was no gender predominance. Twenty-seven patients (82%) had serious intra-abdominal pathology, often requiring a medical procedure. Of those who received antibiotics (28/33, 85%), the median duration of treatment was 21.5 days. Mortality from all causes was 6% at 7 days, 12% at 30 days, and 33% at 1 year. Of 26 isolates available for further testing, all were identified as E. lenta by both commercially available matrix-assisted laser desorption ionization-time of flight mass spectrometry (MALDI-TOF MS) systems, and none were found to harbor a vanA or vanB gene. Of 23 isolates which underwent susceptibility testing, all were susceptible to amoxicillin-clavulanate, cefoxitin, metronidazole, piperacillin-tazobactam, ertapenem, and meropenem, 91% were susceptible to clindamycin, 74% were susceptible to moxifloxacin, and 39% were susceptible to penicillin.
ggerthella lenta is an anaerobic, nonsporulating, Gram-positive bacillus in the Coriobacteriaceae family that was first described in 1935 by Arnold Eggerth (1) . It has since been characterized in more detail (2) and was called Eubacterium lentum until genetic analysis in 1999 placed it in its own distinct genus (3, 4) . Two closely related species, Paraeggerthella hongkongensis and Eggerthella sinensis, have also been described recently (5) (6) (7) . The complete genomic sequence was first published in 2009 (8, 9) .
Due to historical difficulties with laboratory identification, there is a paucity of published data on the spectrum of disease that E. lenta causes and its optimal treatment. E. lenta is part of the normal human intestinal microbiome (10) and has been most commonly associated with infections from a gastrointestinal tract (GIT) source, which are often polymicrobial (11) . Severe, disseminated disease has been described (12) , and overall mortality is significant, ranging from 36% to 43% (13, 14) .
E. lenta is being increasingly recognized in the modern clinical microbiology laboratory due to the widespread uptake of new technologies such as automated phenotypic identification systems and molecular sequencing techniques. More recently, it has been demonstrated that matrix-assisted laser desorption ionizationtime of flight mass spectrometry (MALDI-TOF MS) is capable of rapidly identifying E. lenta (15) (16) (17) .
The use of antimicrobial susceptibility testing (AST) for anaerobes remains restricted to specialized reference laboratories, so antimicrobial therapy for patients with infections due to anaerobic bacteria is often empirical. However, given that resistance among anaerobic organisms is increasing, susceptibility data are important to guide therapy (18) (19) (20) . There are limited published data on the susceptibility profile of E. lenta, and breakpoints are extrapolated from those determined for other species. In 2001, Stinear et al. were developing a rapid PCR-based screening method for detection of fecal carriers of vancomycin-resistant enterococci (VRE) when they identified the vanB locus in Eggerthella lenta, hypothesizing that anaerobic bowel flora may represent the origin of VRE and demonstrating that E. lenta is capable of acquiring vancomycin resistance (21) (22) (23) .
In this study, we have retrospectively reviewed 33 patients with E. lenta bacteremia, which represents the largest published series to date. We describe their clinical features, laboratory identification by both phenotypic and genotypic methods, and AST results.
MATERIALS AND METHODS
Case ascertainment and clinical data collection. This study was conducted at Monash Health, a large health care network encompassing 5 campuses and over 2,200 beds in Melbourne, Australia. Cases were identified by searching our Microbiology database for data from January 2000 to September 2013 for all positive blood cultures with Eubacterium lentum or Eggerthella lenta. Clinical data were collected from medical records. Cases were classified community onset if the positive blood culture was collected within 72 h of admission to the hospital and there was no identifiable prior health care contact, health care associated if the positive blood culture was collected within 72 h of admission and contact with the hospital system (e.g., dialysis, admissions, procedures, etc.) had occurred within 1 month after admission, and nosocomial if the positive blood culture was collected beyond 72 h (26, 27) were calculated. The study was approved by our Human Research Ethics Committee. Blood cultures. E. lenta was isolated from BacT/Alert anaerobic blood culture bottles using a BacT/Alert three-dimensional (3D) automated microbial detection system (bioMérieux, Marcy l'Etoile, France). The number of hours (or days if hour data were not available) to detection of growth was recorded for each case.
Isolate identification. Available isolates were retrieved from storage and purity plated on Oxoid Anaero plates (Thermo Fisher Scientific, Basingstoke, United Kingdom). After 48 h of incubation, they were identified via multiple methods. Phenotypic identification was performed based on Gram staining, colony morphology, and Vitek-2 ANC card (bioMérieux, Marcy, l'Etoile, France) results. MALDI-TOF identification was performed using both available commercial systems, Bruker MS (Bruker Daltonics, Bremen, Germany) and Vitek MS (bioMérieux, Marcy l'Etoile, France) (formerly known as Axima@SARAMIS; Shimadzu). For isolates that could not be retrieved from storage, original phenotypic identification was performed with a RapID-ANA II system (Innovative Diagnostic Systems, Inc., Atlanta, GA).
Bruker MS analysis was performed as previously described (28, 29) . Each isolate was anaerobically grown on a chocolate agar plate for 72 h. The extended direct transfer method was used whereby a single colony was touched and applied as a thin film directly onto a spot on a MALDI target plate, overlaid with 1 l of 70% formic acid, and allowed to dry at room temperature. A 1-l volume of HCCA matrix solution (␣-cyano-4-hydroxy-cinnamic acid-50% acetonitrile-47.5% water-2.5% trifluoroacetic acid) (Sigma-Aldrich) was added to each spot and allowed to dry. Escherichia coli (strain MB11464_1) was used as a calibration standard. Spectrometric measurements were performed using a Microflex LT mass spectrometer (Bruker Daltonik) and analyzed using MALDI Biotyper software (version 3.1). Per manufacturer instructions, a log score value of Ն2.0 met the criteria for species identification. A score of 1.700 to 1.999 allowed correct identification to the level of the genus, while a score of Ͻ1.7 was interpreted as showing no identity.
Vitek MS (bioMérieux) analysis was also performed as previously described (28, 30) . Single colonies from a 72-h brain heart infusion agar plate were directly smeared onto wells of the target plate; 0.5 l of readyto-use 40% formic acid (bioMérieux, Marcy l'Etoile, France) was added to each sample and allowed to air dry at room temperature. A 1-l volume of ready-to-use HCCA matrix solution (bioMérieux, Marcy l'Etoile, France) was added to each spot and allowed to dry. E. coli strain ATCC 8739 was used as a calibration standard. To generate protein mass fingerprints, the FlexiMass-DS target was loaded onto an adapter, prior to insertion into a Vitek MS instrument. Raw spectra were generated with Launchpad v. 2.8 software (Shimadzu-Biotech), and protein mass spectrum fingerprints were then directed to SARAMIS (AnagnosTec GmbH) for analysis. Isolates were identified by comparison with spectra in the reference MS database (containing 3,178 SuperSpectrum [SuperS] entries). Identification at the genus or species level was considered reliable when the score was above the 75% confidence level when matched to the SuperS data, a consensus spectrum for that genus or species compiled from reference spectra of that organism in the database. A result was also acceptable if a "comparison" result, indicating a good match to one or more reference spectra but not to the SuperS data, was obtained.
Bacterial DNA was extracted, amplified, and sequenced using a MicroSEQ 16S rRNA bacterial identification kit (PerkinElmer Applied Biosystems Inc., Foster City, CA, USA). The resulting 16S rRNA gene sequences were then analyzed with MicroSeq 500 software (version 2.2.1). If the sequences were Ն99.0% compatible with the database, the identity was acceptable to the level of the species.
AST. Antimicrobial susceptibility testing (AST) was performed for E. lenta clinical isolates and E. lenta strain ATCC 43055 (31) using the reference agar dilution procedure (Wadsworth method) and Brucella agar supplemented with 5 g/ml hemin plus 1 g/ml vitamin K plus 5% (vol/ vol) laked sheep blood, with a final volume of 20 ml/plate (18 ml agar plus 2 ml antibiotic). The "direct colony suspension" method (32, 33) was used. Plates were incubated in an anaerobic chamber for 48 h in an atmosphere of 4% to 7% CO 2 . An inoculum of 10 5 CFU/spot was used. Antibiotic powders were supplied by Sigma-Aldrich (penicillin, cefoxitin, ceftriaxone, vancomycin, piperacillin-tazobactam, metronidazole, clindamycin), GlaxoSmithKline (amoxicillin-clavulanate), Merck (ertapenem), Pfizer (tazobactam, tigecycline), Bayer (moxifloxacin), and AstraZeneca (meropenem).
Testing for teicoplanin was performed using the Etest method (bioMérieux) (lot number 1002276240) according to the manufacturer's recommended guidelines (34) .
Interpretative criteria. MICs were compared to standard Clinical and Laboratory Standards Institute (CLSI) and European Committee on Antimicrobial Susceptibility Testing (EUCAST) breakpoints (available only for Gram-positive anaerobes) and are reported as susceptible, intermediate, or resistant.
van gene PCR. After incubation for 48 h, the Anaero (Oxoid) plates were swabbed with a dry sterile cotton swab and the organisms were placed into sterile saline solution. Bacteria were pelleted at 10,000 ϫ g for 10 min, and the supernatant was discarded. DNA was extracted from pellets of bacteria using a PureLink DNA miniprep kit with the Gram-positive modification protocol (Invitrogen). DNA was eluted using 200 l of 10 mM Tris (pH 8.5). DNA concentrations were determined by Qubit assay. Real-time PCR for vanA and vanB was performed using a Roche LightCycler FastStart DNA Master HybProbe kit as described by Palladino et al. (35) . Control isolates were strain MLG043 (E. lenta containing vanB [23] ) and clinical isolates of Enterococcus faecium containing vanA and E. faecium containing vanB (22) . 
RESULTS
Clinical data. The clinical characteristics of 33 patients with E. lenta bacteremia are summarized in Tables 1 and 2 . The median age was 68 years (mean, 62.4 Ϯ 23.9; range, 11 to 95), and 17/33 (52%) were male. The median length of stay was 11 days (24 Ϯ 26; 1 to 94), and 10/33 (30%) patients were admitted to the intensive care unit (ICU). The majority (64%) of patients had community onset disease, and 39% had polymicrobial bacteremia, with a variety of enteric organisms isolated. Blood cultures flagged positive after a median of 3 days of incubation (2.85 Ϯ 1.09; 1 to 5). Time to positivity could be determined for 30 patients; the median time was 65.5 h (72.5 Ϯ 25.2; 40.1 to 122.6). The most common presenting symptoms were fever (82%) and abdominal pain (64%). A total of 82% of patients had the GIT identified as the likely source. The median SAPS II score was 25 (27 Ϯ 12.2; 6 to 64), the median Charlson comorbidity score was 2 (2.45 Ϯ 2.25; 0 to 7), and the Pitt bacteremia score was 2 (2.15 Ϯ 1.9; 0 to 8). A total of 67% of patients had an abnormal white cell count (WCC; Ͻ4 ϫ 10 9 /liter or Ͼ11 ϫ 10 9 /liter) at the time of bacteremia, and the C-reactive protein (CRP) level was elevated in all 31 patients in whom it was measured.
Abdominal imaging was performed in more than half of the total number of patients, and in three-fourths, an abnormality was found. Treatment was dependent on the underlying pathology, with 21/33 patients undergoing at least one procedure. Twelve patients underwent surgery, 3 had radiologically guided procedures (e.g., drainage of abscess), and 11 proceeded to diagnostic and/or therapeutic endoscopy. Antibiotic treatment was variable. Five patients received no antibiotic therapy, and all were alive at 1 year. These were generally patients with self-limiting illnesses who had clinically improved by the time their blood cultures had flagged positive, so their treating clinicians had decided that antibiotic therapy was not indicated. Of those treated with antibiotics, the median duration of treatment was 21.5 days (36.7 Ϯ 56.2; 2 to 301). A wide range of antibiotics were used, most often metronidazole-containing regimens (8 patients) or amoxicillin-clavulanate (6 patients). A 1-year follow-up was available for all patients. Mortality from all causes was 6% at 7 days, 12% at 30 days, and 33% at 1 year.
Isolate identification. A total of 28 isolates were available for comprehensive testing. All were confirmed as E. lenta using a Vitek-2 ANC card and 16S rRNA gene sequencing. Five older isolates originally identified by Rapid-ANA were not viable. Twentysix isolates were available for testing in the Bruker MS system, which accurately identified all 26 to the genus level (log score, Ͼ1.7), including 19/26 as E. lenta (Ͼ2.0). Twenty-three isolates were tested in the bioMérieux MALDI system; all were identified as E. lenta with a 99.9% confidence value.
Antimicrobial susceptibility testing (AST). Table 3 shows the AST results for 23 E. lenta isolates. Applying CLSI interpretative criteria (32) , all isolates were susceptible to amoxicillin-clavulanate, cefoxitin, metronidazole, ertapenem, piperacillin-tazobactam, and meropenem. Susceptibility to clindamycin was 91%, to moxifloxacin was 74%, and to penicillin was 39%; all isolates were resistant to ceftriaxone. No CLSI breakpoints are available for tigecycline, vancomycin, or teicoplanin; however, all isolates had an MIC of Յ1 mg/liter. Using EUCAST breakpoints, interpretations were similar, except for penicillin and piperacillin-tazobactam, to which no isolates were susceptible (36) .
van gene PCR. A total of 23 E. lenta isolates were tested; all were negative for vanA and vanB genes. All positive controls tested positive.
DISCUSSION
Our report represents the largest, most comprehensive study of patients with E. lenta bacteremia described in the literature to date. Our findings suggest that E. lenta bacteremia is associated with a spectrum of disease, ranging from asymptomatic bacteremia (generally seen in the setting of a transient gastrointestinal illness) to part-polymicrobial bacteremia from an intra-abdominal source (e.g., perforated viscus) to severe monomicrobial disseminated disease. A significant proportion of our cohort had serious GIT pathology, often requiring surgical or radiological intervention and ICU admission to achieve cure. This suggests that when identified in blood cultures, E. lenta should not necessarily be dismissed as a contaminant but rather should represent a trigger for more-detailed evaluation of the patient and appropriate abdominal diagnostic imaging.
Published reports of E. lenta bacteremia are outlined in Table 4 . Our cohort has some differences from previous case series. Venugopal et al. (14) provided detailed clinical information on 25 cases but no microbiological data. They reported a higher proportion of health care onset bacteremias (50%). Only 44% of their patients had an abdominal disease source, and 40% had a skin or softtissue disease source, most often infected decubitus ulcers, associated with high (44%) rates of hospitalized, bedridden patients. They identified ICU admission and absence of fever on the day of admission as risk factors for increased 30-day mortality, which was much higher than in our series (36% versus 12%). Interestingly, of our 10 patients admitted to ICU, all were alive at 30 days, and of the 4 patients dead at 30 days, 2 were febrile on admission. Lee et al. (13) described 7 patients with E. lenta bacteremia. They had a comparatively lower median age of 56, 71% were in the community onset category, and 43% had an underlying malignancy. The report did not identify the source of infections, although 30% had "abdominal symptoms." Lau et al. (5, 6) described 5 cases of E. lenta bacteremia, 3 of which were polymicrobial and 2 of which occurred in patients with infected decubitus ulcers. In addition to these series, there are 6 published case reports of patients with E. lenta bacteremia. Two describe severe, disseminated disease with multifocal abscesses requiring extended courses of intravenous antibiotics and/or surgical drainage to cure (12, 38) . There are other published cases of severe E. lenta infection without definite bacteremia, including reports of frontal sinusitis (43), pyomyositis (44) , cutaneous abscesses (45), spondylodiscitis (46) , and liver abscess (47) . E. lenta has also been implicated in the pathogenesis of bacterial vaginosis (48) (49) (50) and linked to appendicitis in children (51) .
Identification of E. lenta by MALDI-TOF was initially not reliable due to the limited number of anaerobic bacterial species included in earlier versions of the databases (28, 52) . In 2011, Justesen et al. (30) reported that one E. lenta isolate was identified by the Bruker MS method using an updated database but not by the Shimadzu MALDI-TOF MS method. In more recent studies, E. lenta has been correctly identified using the Bruker MS method: 2/2 isolates to the species level (15), 8/8 isolates to the genus level and 6/8 isolates to the species level (16), and 8/10 isolates to the genus level and 2/10 isolates to the species level (17) . Our study showed that E. lenta can be reliably identified using both available commercial MALDI-TOF MS platforms. Access to anaerobic AST is problematic, however, and a lack of available data has led to breakpoint extrapolation from other anaerobic species to E. lenta. Our antimicrobial susceptibility results are consistent with those of previous studies (Table 5) , which have shown that isolates are frequently resistant to penicillin and have variable susceptibility to clindamycin and moxifloxacin but remain susceptible to amoxicillin-clavulanate, cefoxitin, metronidazole, and carbapenems. In summary, Eggerthella lenta appears to be a significant human pathogen that is often associated with serious GIT pathology. If the diagnosis is not apparent at the time of isolation of this organism in blood cultures, detailed investigation of the abdomen should be undertaken. E. lenta is likely to be increasingly identified given the ease and rapidity of MALDI-TOF MS and the uptake of this technology into many clinical microbiology laboratories worldwide. The most reliable antibiotic treatment options appear to be cefoxitin, metronidazole, amoxicillin-clavulanate, and the carbapenems, with the role of piperacillin-tazobactam currently unclear. However, with rising rates of resistance in anaerobes increasingly reported, AST should be considered to guide therapy, particularly in serious infections. Յ0.06, 100 1 to 2, 100 a All studies utilized CLSI agar dilution methodology and CLSI breakpoints. b PEN, penicillin (*, ampicillin); FOX, cefoxitin; CRO, ceftriaxone; AMC, amoxicillin-clavulanate; TZP, piperacillin-tazobactam; CLI, clindamycin; MOX, moxifloxacin; MET, metronidazole; ERT, ertapenem; MEM, meropenem; TGC, tigecycline; VAN, vancomycin. 
